Fomivirsen sodium

福米韦生钠

Report date: 2022/05/12 17:20:45
NME

Base Information

Drug NameFomivirsen sodium
Drug Alias Name福米韦生FomivirsenumVitraveneISIS-2922
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionProtein biosynthesis inhibitors
TargetsNot applicable
Therapy Area/IndicationsHIV InfectionsCytomegalovirus Retinitis
Global Approved IndicationsCytomegalovirus Retinitis
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date1998/08/26
Country/TerritoryUnited StatesEU
CombinationsNo
Global Highest StatusWithdrawn
Highest Status in ChinaN/A
Originator CompaniesN/A
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesIonis Pharmaceuticals IncNovartis Ophthalmics Europe LtdNovartis Pharma Ag
Active IndicationsN/A
Inactive IndicationsHIV InfectionsCytomegalovirus Retinitis

Other Information

ATC CodeS01AD08
Related LinksWikipediaKEGG